Marc Straus is an American oncologist, art collector, poet, and writer.[1] He is the author of more than 40 scientific papers on the treatment of various types of cancer. Straus was among the first oncologists to introduce the use of continuous infusion for the delivery of chemotherapy, a practice that has since become standard.[2]
Straus is the founder of Hudson Valley MOCA and the Marc Straus Gallery in New York City.
Early life and education
Straus was raised in Long Island and in Brooklyn.[1] His father was an orphaned immigrant who came to the United States at age 15 and later owned a textile business on Manhattan’s Lower East Side. Growing up, Straus worked in the shop on Sundays.[3]
Straus served as SesenioCacancer rcer Research internist at the National Cancer Institute Veteran’s Administration (NCI-VA) Medical Oncology Branch from 1972 to 1974. During this period, he also served as head of the NCI-VA Cell Kinetics Laboratory, as NCI-VA Director of Medical Education, and as Executive Officer of the NCI Work Group for Therapy of Lung Cancer. At the National Cancer Institute he worked on cancer drug studies in mice which established optimal ways of combining different drugs to improve outcomes. During this time he had a number of studies published in cancer research journals.[5][6]
In 1973 he was recruited as Chief of Oncology and Associate Professor of Medicine at Boston University Medical Center[4] where his clinical and research work focused primarily on breast and lung cancers.[7][8][9] While at BU, Straus was among the recipients of the Ten Outstanding Young Leaders Award from the Greater Boston Chamber of Commerce.[10]
From 1982 to 2008, he headed Access Medical Group, a multi-specialty group in the Hudson Valley, New York, which had 36 doctors. In 1997 he founded a medical management company that managed 300 doctors in New York state.
In 1982, Straus started CarePlus, a publicly trade home nutrition company.[citation needed] In 1983 he founded Medical Registry Services, a software company pthat providescancer registry software support for hospitals. In 2008 he and his son, Ari, founded MDINR, a software company wthatsupported doctors treating patients with the anti-coagulant, Coumadin, also sold under the brand name Warfarin.[citation needed]
Straus was president of The Oxford Medical Group, P.C. and chief executive officer and chair of MDx Med-Care.[15]
Writing career
In 1991 Straus took a poetry workshop at the 92nd Street Y in New York City. He was later awarded a writing residency at Yaddo, an artists' community located on a 400-acre estate in Saratoga Springs, New York.[16] In 1999 Straus was awarded the Robert Penn Warren Award Lecture in the Humanities from Yale University Medical School.[15][17]
Straus left his full-time medical practice in 2006 and began focusing on his poetry. By 2009 he had published more than 100 poems and three books.[1] His poems have been published in more than 100 journals including Kthe enyon Review, Ploughshares, and TriQuarterly.His work often deals with doctor patient communication. Many poems are in the voices of patients or doctors.[18]
Straus' work was the basis of a 2004 exhibition at Lehigh University called "THE BRIDGE: A Journey Through Illness" with a catalog and essay by poet John Yau.[19]
Contemporary art
Straus made his first art acquisition of four Milton Resnick paintings while still a teenager.[3]
Straus and his wife, Livia, began collecting contemporary art by 1966. Their collection has been featured in The NY Times,[20][21]Forbes, Harper's Bazaar, Contemporanea,[22]Art & Antiques, and ARTnews.[23] The couples' personal art collection includes four pop art prints and one oil painting by Roy Lichtenstein, two works by Claes Oldenburgs (plaster loaves of bread from 1961 and a molded rubber screw from 1975), and three works by Jasper Johns.[20] Their collection has been listed in Art & Antiques as one of the Top 100 collections in the US.[24]
Straus has written some 35 articles in leading publications on art collecting and art criticism[25][26][27] and was president of the Aldrich museum of Contemporary Art in Ridgefield Connecticut.[28]
In 2002 the couple founded the Hudson Valley Center for Contemporary Art, turning a 12,000 sq ft former paneling factory in Peekskill NY into a space for cutting-edge contemporary art by artists like Folkert de Jong and Thomas Hirschhorn.[29] The facility was later renamed the Hudson Valley MOCA. Its focus is on emerging artists from around the world and supporting an economically challenged area with education programs.[30]
Straus opened MARC STRAUS, a contemporary art gallery on Grand Street, Manhattan, in 2011. NYC across the street from where his father's store had been. The gallery represents 24 artists from 16 different counties. In 2014 Flash Art listed MARC STRAUS as among the top 100 galleries in the world. [citation needed]
Philanthropic work
In 2001 Straus and his wife established the Marc and Livia Straus Foundation to support their artistic endeavors.[31]
Straus was a Trustee of Franklin and Marshall College from 1994 – 2004.[32] He also funded the establishment of the school’s first Jewish Studies program.[33]
In 2017, the Strauses donated the former Devitt’s Medical Arts Building in New Windsor, NY to Abilities First, a regional provider of education, vocational development, and residential for individuals with developmental disabilities.[34] The gift, valued at $3.2M, was the largest in the organization’s history. The building became the first Orange County location for the Abilities First School and was named in honor of Straus and his family.[35]
Personal life
Straus and his wife met while the two were teenagers.[3] They live in Chappaqua, NY.[36]
Allegations of research misconduct
In June 1978, two nurses and two trainees who worked with him at the Boston University School of Medicine (BUSM) alleged that Straus had ordered them to falsify patients' records,[37] had failed to get proper consent from patients, and had improperly administered drugs.[37][38] Straus denied personal involvement in wrongdoing[11][39] asserting his innocence[40] and maintaining that he had been framed by disgruntled subordinates.[41][42]
Straus resigned from his posts at Boston University Medical Center Hospital (since 1996 part of Boston Medical Center) and BUSM.[43][11] later that month. Following his resignation, Straus made multiple requests for external peer review of the charges against him. BU refused, leading Straus to conclude that the internal evaluation of his work was tainted because of investigator bias and lack of protection for the records.[44]
In 1980, while the investigation was ongoing, the National Cancer Institute awarded Straus a three-year grant of about $910,000 to conduct research. In 1981, Vincent T. DeVita Jr., Director of the NCI testified before Congress, saying that "his agencies award last year of a $910,000 research grant to a scientist last year... (Straus) …on the ground that ...the charges …had not yet been proven.[45]
One year later, Straus filed a $33 million lawsuit against five of his former co-workers, charging they had conspired to discredit his work.[46] Straus strongly denied that he had engaged in any wrongdoing alleging that his signature had been forged.[47]
Ruth Moran, MD, PhD, Straus’ lab chief from 1972 testified:
"Having worked side by side with Dr. Straus for 8 years ...the allegations to be totally inconsistent with what I know his scientific standards to be... The (BUMC) committee refused to see me. Dr. Straus’ chief data manager (Mary Jane Rimmer, R.N.) reported to me ... that she had always been instructed by Dr. Straus to record data accurately."[48]
"Scientists Supporting the Rights of Marc J. Straus, M.D." convened 78 cancer doctors and researchers in 1981, chaired by Mendel Krim, M.D. and Ruth Moran, MD Ph.D. They petitioned Vincent T. DeVita, Director NCI, and Arthur Hayes, Commissioner of the FDA, for a unitary blue ribbon review with full disclosure of relevant documents.[49]
After becoming convinced that this legal outcome was unavoidable, Straus settled with the U.S. Department of Health and Human Services in 1982, acknowledging that false reports were submitted without his knowledge.[39][40][41]
In October 1982, Straus published a paper in Cancer Treatment Reports, a journal funded by the National Cancer Institute. The propriety of that publication was questioned in the journal Science.[42] Straus continued to publish scientific clinical studies through 1998.[50]
Books
LUNG CANCER Clinical Diagnosis and Treatment (1977) Edited by Marc J. Straus, M.D. Grune & Stratton[51]
LUNG CANCER Clinical Diagnosis and Treatment (1983) Edited by Marc J. Straus, M.D. Grune & Stratton[51]
Straus, Marc J. "Combination chemotherapy in advanced lung cancer with increased survival." Cancer 38.6 (1976): 2232-2241.
Straus, Marc J., et al. "Estrogen receptor heterogeneity and the relationship between estrogen receptor and the tritiated thymidine labeling index in human breast cancer." Oncology 39.4 (1982): 197–200. Straus, Marc J., and Ruth E. Moran. "Cell cycle parameters in human solid tumors." Cancer 40.4 (1977): 1453–1461.
Straus, Marc J., and Ruth E. Moran. "The cell cycle kinetics of human breast cancer." Cancer 46.12 (1980): 2634–2639.
Moran, Ruth E., and Marc J. Straus. "Synchronization of L1210 leukemia with hydroxyurea infusion and the effect of subsequent pulse dose chemotherapy." Cancer Treat Rep 64 (1980): 81–6.
Moran, Ruth E., and Marc J. Straus. "Cytokinetic analysis of L1210 leukemia after continuous infusion of hydroxyurea in vivo." Cancer research 39.5 (1979): 1616–1622.
Moran, Ruth E., and Marc J. Straus. "Effects of pulse and continuous intravenous infusion of cis-diamminedichloroplatinum on L1210 leukemia in vivo." Cancer research 41.12 Part 1 (1981): 4993–4996.
Straus, Marc J. "Cytokinetic Chemotherapy Design for the Treatment of Advanced Lung Cancer 1, 2." Cancer treatment reports 63.5–8 (1979): 767. Cytokinetic analysis of L1210 leukemia after continuous infusion of hydroxyurea in vivo
Straus, Marc J., Vivian Sege, and Sung C. Choi. "The effect of surgery and pretreatment or posttreatment adjuvant chemotherapy on primary tumor growth in an animal model." Journal of surgical oncology 7.6 (1975): 497–512.
Straus, Marc J., et al. "The uptake, excretion, and radiation hazards of tritiated thymidine in humans." Cancer research 37.2 (1977): 610–618.
Straus, Marc J., Nathan Mantel, and Abraham Goldin. "The Effect of the Sequence of Administration of Cytoxan and Methotrexate on the Life-span of L1210 Leukemic Mice." Cancer research 32.2 (1972): 200–207
^Straus MJ, Mantel N, Goldin A (1971). "Effects of priming dose schedules in methotrexate treatment of mouse leukemia L1210". Cancer Research. 31 (10): 1429–33. PMID5095131.
^Straus MJ, Straus SE, Krezoski S, Battiste L (1977). "The uptake, excretion, and radiation hazards of tritiated thymidine in humans". Cancer Research. 37 (2): 610–8. PMID832281.
^Straus MJ (1979). "New developments in the treatment of advanced lung cancer". The American Review of Respiratory Disease. 120 (5): 967–71. doi:10.1164/arrd.1979.120.5.967 (inactive November 1, 2024). PMID228574.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)